BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34537078)

  • 1. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
    Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
    Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.
    Larsen AC; Dahmcke CM; Dahl C; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
    JAMA Ophthalmol; 2015 Nov; 133(11):1295-303. PubMed ID: 26425792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
    Tas F; Erturk K
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.
    Strom T; Torres-Roca JF; Parekh A; Naghavi AO; Caudell JJ; Oliver DE; Messina JL; Khushalani NI; Zager JS; Sarnaik A; Mulé JJ; Trotti AM; Eschrich SA; Sondak VK; Harrison LB
    J Natl Compr Canc Netw; 2017 Apr; 15(4):473-482. PubMed ID: 28404758
    [No Abstract]   [Full Text] [Related]  

  • 9. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
    Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.
    Sheng X; Li S; Chi Z; Si L; Cui C; Mao L; Lian B; Tang B; Wang X; Yan X; Kong Y; Dai J; Guo J
    Br J Ophthalmol; 2015 Jul; 99(7):990-6. PubMed ID: 25595173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
    Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
    Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
    Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
    Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
    Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
    Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
    Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
    Cancer Immunol Immunother; 2009 Jul; 58(7):1085-94. PubMed ID: 19039588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
    BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.